Feb 8 (Reuters) - Aptahem AB  APTA.TE :
    * APTAHEM REPORTS DELAY IN DELIVERY OF ITS DRUG PRODUCT
    * APTAHEM ANTICIPATES THAT COMMENCEMENT OF PLANNED CLINICAL
STUDY
FOR APTA-1 WILL BE DELAYED.
    * MANUFACTURE OF ITS DRUG PRODUCT HAS BEEN DELAYED AS A
RESULT OF
TECHNICAL CHALLENGES
    * A NEED TO HAVE MORE DRUG PRODUCT MANUFACTURED WAS
ANNOUNCED IN A
PRESS RELEASE ON AUGUST 28, 2018 DURING PRECLINICAL TOXICOLOGY
PROGRAM.
    * PLANNED CLINICAL STUDY WILL NOT START DURING Q3 THIS YEAR
AS
PREVIOUSLY COMMUNICATED.
    * DELAY IS DUE TO A SERIES OF TECHNICAL DIFFICULTIES THAT
HAVE
BEEN ENCOUNTERED DURING CONTRACT MANUFACTURER'S PRODUCTION.

Source text for Eikon:  ID:nWkr5vbK5M 
Further company coverage:  APTA.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))